NCT03763604 2024-12-16Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast CancerEli Lilly and CompanyApproved for marketing
NCT02792725 2017-10-31Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast CancerEli Lilly and CompanyApproved for marketing